BETHLEHEM, Pa.- B. Braun has announced it will wind down operations of a medical device unit.
B. Braun Interventional Systems (BIS) will be discontinued through a phased approach, the company said in a news release; commercial sales will continue through early 2027.
There is no immediate disruption to product supply, B. Braun said.
The division’s product portfolio includes catheters used in heart and vascular procedures, stents, drainage bags, and other surgical tools and devices.
According to B. Braun’s website, the BIS division is based at its North American headquarters at 824 12th Avenue in Bethlehem.
A company spokesperson said the decision to close the division is part of ongoing efforts “to focus resources on strategic priorities and core businesses.”
40 employees across the U.S. will be impacted, the spokesperson said. Those employees are being provided with transition support services.
It’s the second restructuring announced for B. Braun in recent months.
Over the summer, B. Braun’s subsidiary Central Admixture Pharmacy Services (CAPS) announced it was ending 503B compounding operations, which impacted 173 employees at a pair of locations in Upper Macungie Township.
Texas-based Quva Pharma later announced it had acquired “a range of essential medications” from CAPS. Its 503B manufacturing facilities include a location outside Bloomsbury, New Jersey in Greenwich Township.
According to its website, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. B. Braun’s global headquarters is based in Germany.